MBX Biosciences (NASDAQ:MBX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of MBX Biosciences (NASDAQ:MBX) from a hold rating to a sell rating in a research report sent to investors on Monday.

Several other equities research analysts have also recently weighed in on MBX. Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a report on Tuesday, April 21st. Barclays boosted their target price on MBX Biosciences from $66.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Truist Financial upped their target price on MBX Biosciences from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Citigroup reaffirmed an “outperform” rating on shares of MBX Biosciences in a research note on Tuesday, May 12th. Finally, Citizens Jmp lifted their price target on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.00.

MBX Biosciences Price Performance

NASDAQ MBX opened at $60.14 on Monday. MBX Biosciences has a 1 year low of $9.63 and a 1 year high of $66.55. The stock has a market capitalization of $2.86 billion, a PE ratio of -27.21 and a beta of 0.16. The business’s 50-day moving average is $43.37 and its 200 day moving average is $37.10.

Institutional Trading of MBX Biosciences

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in shares of MBX Biosciences by 4,131.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after acquiring an additional 1,446 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of MBX Biosciences during the fourth quarter valued at approximately $28,000. Strs Ohio boosted its position in shares of MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after purchasing an additional 900 shares in the last quarter. Royal Bank of Canada grew its stake in MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in MBX Biosciences by 117.9% in the third quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock worth $51,000 after purchasing an additional 1,567 shares during the period.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.